Table 3.
Thromboembolic events in subjects with COVID-19 without hospitalization (exposed) and without COVID-19 (nonexposed) groups.
| Age (y) | COVID-19 status | Early (0 to <60 d) |
Late (60 to <180 d) |
Long term (from 180 d) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Na | Total events | HR (CI) Model 2b |
Nc | Events | Event rate (per 1000 y) | HR (CI) Model 2b |
Nc | Events | Event rate (per 1000 y) | HR (CI) Model 2d |
||
| VTE | ||||||||||||
| 18-54 | Exposed | 710,570 | 319 | 3.07 (2.66-3.54) | 710,126 | 206 | 0.92 | 1.10 (0.95-1.28) | 653,695 | 198 | 0.9 | 1.20 (1.02-1.40) |
| Nonexposed | 3,550,407 | 502 | 3,446,525 | 891 | 0.84 | 3,022,616 | 735 | 0.76 | ||||
| 54-64 | Exposed | 121,640 | 183 | 3.44 (2.83-4.17) | 121,298 | 91 | 2.32 | 0.86 (0.68-1.08) | 116,428 | 93 | 2.24 | 1.01 (0.81-1.27) |
| Nonexposed | 608,108 | 260 | 593,679 | 500 | 2.65 | 550,608 | 431 | 2.3 | ||||
| 65-74 | Exposed | 42,360 | 126 | 3.76 (2.96-4.77) | 41,715 | 75 | 5.6 | 1.47 (1.14-1.90) | 39,740 | 59 | 4.24 | 1.10 (0.83-1.47) |
| Nonexposed | 211,901 | 159 | 209,148 | 257 | 3.86 | 196,413 | 255 | 3.77 | ||||
| 75-84 | Exposed | 18,472 | 90 | 3.86 (2.88-5.17) | 16,600 | 57 | 10.88 | 1.27 (0.94-1.70) | 15,457 | 43 | 6.73 | 1.05 (0.75-1.47) |
| Nonexposed | 92,609 | 112 | 91,367 | 234 | 8.09 | 85,665 | 216 | 5.74 | ||||
| Total | Exposed | 893,042 | 718 | 3.32 (3.01-3.66) | 889,739 | 429 | 1.52 | 1.10 (0.99-1.22) | 825,320 | 393 | 1.39 | 1.11 (0.99-1.24) |
| Nonexposed | 4,463,025 | 1033 | 4,340,719 | 1882 | 1.4 | 3,855,302 | 1637 | 1.3 | ||||
| PE | ||||||||||||
| 18-54 | Exposed | 710,889 | 192 | 4.04 (3.32-4.91) | 710,568 | 83 | 0.37 | 1.11 (0.88-1.41) | 654,205 | 76 | 0.34 | 1.16 (0.90-1.50) |
| Nonexposed | 3,552,215 | 227 | 3,448,541 | 359 | 0.34 | 3,024,882 | 289 | 0.3 | ||||
| 54-64 | Exposed | 121,777 | 106 | 3.56 (2.75-4.61) | 121,503 | 52 | 1.32 | 0.97 (0.72-1.31) | 116,657 | 44 | 1.06 | 0.98 (0.70-1.35) |
| Nonexposed | 608,788 | 143 | 594,449 | 262 | 1.39 | 551,527 | 212 | 1.13 | ||||
| 65-74 | Exposed | 42,445 | 82 | 3.83 (2.83-5.17) | 41,834 | 47 | 3.5 | 1.70 (1.22-2.36) | 39,874 | 28 | 2.01 | 0.95 (0.63-1.44) |
| Nonexposed | 212,270 | 97 | 209,565 | 139 | 2.08 | 196,887 | 140 | 2.07 | ||||
| 75-84 | Exposed | 18,541 | 64 | 4.32 (3.02-6.19) | 16,683 | 37 | 7.02 | 1.29 (0.90-1.86) | 15,550 | 31 | 4.82 | 1.36 (0.91-2.04) |
| Nonexposed | 92,804 | 70 | 91,594 | 150 | 5.17 | 85,936 | 123 | 3.26 | ||||
| Total | Exposed | 893,652 | 444 | 3.85 (3.38-4.38) | 890,588 | 219 | 0.77 | 1.17 (1.01-1.35) | 826,286 | 179 | 0.63 | 1.08 (0.92-1.28) |
| Nonexposed | 4,466,077 | 537 | 4,344,149 | 910 | 0.67 | 3,859,232 | 764 | 0.61 | ||||
| DVT | ||||||||||||
| 18-54 | Exposed | 710,740 | 141 | 2.22 (1.82-2.72) | 710,465 | 130 | 0.58 | 1.06 (0.87-1.28) | 654,067 | 134 | 0.61 | 1.21 (1.00-1.47) |
| Nonexposed | 3,551,362 | 310 | 3,447,596 | 582 | 0.55 | 3,023,786 | 490 | 0.51 | ||||
| 54-64 | Exposed | 121,744 | 83 | 2.98 (2.26-3.92) | 121,494 | 44 | 1.12 | 0.71 (0.51-0.99) | 116,657 | 58 | 1.4 | 1.06 (0.80-1.41) |
| Nonexposed | 608,648 | 139 | 594,297 | 278 | 1.47 | 551,337 | 256 | 1.37 | ||||
| 65-74 | Exposed | 42,444 | 50 | 3.42 (2.37-4.91) | 41,851 | 30 | 2.23 | 1.12 (0.75-1.66) | 39,900 | 35 | 2.5 | 1.26 (0.87-1.84) |
| Nonexposed | 212,233 | 73 | 209,538 | 135 | 2.02 | 196,855 | 131 | 1.93 | ||||
| 75-84 | Exposed | 18,545 | 31 | 3.23 (2.02-5.18) | 16,696 | 23 | 4.36 | 1.31 (0.82-2.08) | 15,566 | 15 | 2.33 | 0.74 (0.43-1.27) |
| Nonexposed | 92,835 | 47 | 91,629 | 91 | 3.13 | 85,993 | 106 | 2.81 | ||||
| Total | Exposed | 893,473 | 305 | 2.62 (2.28-3.02) | 890,506 | 227 | 0.8 | 0.99 (0.86-1.15) | 826,190 | 242 | 0.86 | 1.14 (0.99-1.31) |
| Nonexposed | 4,465,078 | 569 | 4,343,060 | 1,086 | 0.8 | 3,857,971 | 983 | 0.78 | ||||
DVT, deep venous thrombosis; HR, hazard ratio; PE, pulmonary embolism; VTE, venous thromboembolism.
a
Excluding patients with events occurring between January 1, 2020, and day of diagnosis of COVID-19.
b
Model 1 with adjustment limited to age and sex is presented in Supplementary Table S6 for completeness.
c
Numbers that were alive, had not experienced an event, and was still in follow-up.
d
Model 2 is adjusted for age, sex, obesity, hypertension, need for assisted living, born in a Nordic country, education, and Charlson Comorbidity Index.